// App-Quantinova.ai

400.0 : The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC).

Researchers

Presenter

  • Mohammed Abdullah Alghamdi

Principal Investigators

  • Richard Lee-Ying

  • Mina Swiha

  • Kelvin K. Chan

  • Winson Y. Cheung

  • Maria Ho

  • Vincent C. Tam

Medical Centers

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

  • Cross Cancer Institute, Edmonton, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved